BioMarin Pharmaceutical Inc. (BMRN) Trading 1.5% Higher
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded up 1.5% on Wednesday . The stock traded as high as $93.37 and last traded at $93.14, with a volume of 796,449 shares traded. The stock had previously closed at $91.74.
Several research firms have recently commented on BMRN. Cowen and Company reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Saturday, April 30th. William Blair set a $116.00 price target on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, July 28th. Jefferies Group reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday. Vetr raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $110.24 price target for the company in a research report on Tuesday, August 2nd. Finally, Oppenheimer Holdings Inc. reissued a “hold” rating and issued a $99.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, April 26th. Three equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $121.01.
The stock has a 50-day moving average price of $91.84 and a 200 day moving average price of $84.87. The firm’s market cap is $15.25 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($2.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $2.09. The business earned $300.10 million during the quarter, compared to the consensus estimate of $278.75 million. During the same period last year, the business earned ($0.51) earnings per share. BioMarin Pharmaceutical’s revenue was up 20.0% compared to the same quarter last year. Analysts forecast that BioMarin Pharmaceutical Inc. will post ($3.96) EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $91.49, for a total transaction of $3,812,022.34. Following the completion of the sale, the chief executive officer now directly owns 420,250 shares of the company’s stock, valued at approximately $38,448,672.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brian Mueller sold 287 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $100.00, for a total value of $28,700.00. Following the sale, the vice president now directly owns 14,260 shares of the company’s stock, valued at $1,426,000. The disclosure for this sale can be found here.
Other hedge funds have made changes to their positions in the company. RS Investment Management Co. LLC increased its stake in shares of BioMarin Pharmaceutical by 80.2% in the fourth quarter. RS Investment Management Co. LLC now owns 99,240 shares of the company’s stock worth $10,396,000 after buying an additional 44,180 shares during the period. Utah Retirement Systems boosted its stake in BioMarin Pharmaceutical by 0.3% in the fourth quarter. Utah Retirement Systems now owns 28,781 shares of the company’s stock worth $3,016,000 after buying an additional 100 shares during the period. Finally, I.G. Investment Management LTD. boosted its stake in BioMarin Pharmaceutical by 20.1% in the fourth quarter. I.G. Investment Management LTD. now owns 32,380 shares of the company’s stock worth $3,392,000 after buying an additional 5,430 shares during the period.
BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.